VT204: A Potential Small Molecule Inhibitor Targeting KRASG12C Mutation for Therapeutic Intervention in Non-Small Cell Lung Cancer
Technology in Cancer Research & Treatment · 2024
DOI: 10.1177/15330338241264853 ↗Kurz gefasst
Fachartikel in der Zeitschrift Technology in Cancer Research & Treatment, 2024. Verfasst von Xuechao Yang und 4 weiteren Autor:innen. Beteiligte Einrichtung: College of Biomedical Industry, Guilin Medical University, Guilin, Guangxi, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Cell Proliferation, Apoptosis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Xuechao Yang, Xiaoqun Duan.
Abstract (Originalsprache)
Objectives
The development of effective treatments for non-small cell lung cancer (NSCLC), particularly targeting the KRASG12C mutation, remains a challenge. In this study, we investigated the therapeutic potential of VT204, a small molecule inhibitor of KRASG12C, in NSCLC.
Methods
To achieve the objectives, we conducted a comprehensive set of experimental methods. In vitro experiments involved the investigation of VT204 on proliferation, apoptosis, cell cycle dynamics, migration, invasion, and on the RAF/MEK/ERK signaling pathway in NCI-H358 cells. In addition, in vivo experiments were performed to evaluate the influence of VT204 on tumor growth.
Results
We demonstrated that VT204 effectively suppressed cell proliferation in NCI-H358 cells, with significant inhibition observed at a concentration of 8 μM. Colony formation assays further supported the inhibitory effect of VT204 on NCI-H358 cell growth. Moreover, VT204 exhibited notable effects on suppressing migration and invasion capacities of NCI-H358 cells, indicating its potential as a metastasis-inhibiting agent. Mechanistic investigations revealed that VT204 induced apoptosis and G2M-phase cell cycle arrest in NCI-H358 cells. Additionally, VT204 modulated the RAF/MEK/ERK signaling pathway, leading to reduced phosphorylation of ERK. In vivo studies using xenograft models confirmed the inhibitory effect of VT204 on NCI-H358 tumor growth.
Conclusion
These findings highlight VT204 as a promising therapeutic candidate for NSCLC targeting the KRASG12C mutation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Biomedical Industry, Guilin Medical University, Guilin, Guangxi, China.
- Suzhou Xuhui Analysis Co., Ltd, Kunshan, Jiangsu, China.
- School of Pharmacy, Faculty of Medicine, Macau University of Science and Technology, Macau, China.
- College of Pharmacy, Guilin Medical University, Guilin, Guangxi, China.
ORCID-Profile: Xuechao Yang
Förderung
- Xuechao Yang
- Xiaoqun Duan
Zitieren
APA
Yang, X., Zhang, S., Yang, Y., Duan, X., & Li, X. (2024). VT204: A Potential Small Molecule Inhibitor Targeting KRASG12C Mutation for Therapeutic Intervention in Non-Small Cell Lung Cancer. Technology in Cancer Research & Treatment. https://doi.org/10.1177/15330338241264853
Vancouver
Yang X, Zhang S, Yang Y, Duan X, Li X. VT204: A Potential Small Molecule Inhibitor Targeting KRASG12C Mutation for Therapeutic Intervention in Non-Small Cell Lung Cancer. Technology in Cancer Research & Treatment. 2024. doi:10.1177/15330338241264853
BibTeX
@article{Yang2024,
author = {Yang, Xuechao and Zhang, Shu and Yang, Yang and Duan, Xiaoqun and Li, Xiaochuan},
title = {VT204: A Potential Small Molecule Inhibitor Targeting KRASG12C Mutation for Therapeutic Intervention in Non-Small Cell Lung Cancer},
journal = {Technology in Cancer Research & Treatment},
year = {2024},
doi = {10.1177/15330338241264853}
}
EUVIMED